Core B evaluates and follows all participants entered into the studies of the program project. It uses an established clinical and psychometric protocol at entry and annually thereafter to obtain clinical, neurological, and behavioral data to carefully characterize each participant in support of each of the 3 Projects of this Program Project Grant (PPG).
Specific Aims of Core B are: 1. Maintain the current active cohort (n=225) of participants, carefully characterized as to the presence or absence of symptomatic AD, to support longitudinal studies of the clinical, cognitive, behavioral and biomedical correlates of symptomatic Alzheimer's disease (AD) in comparison with normal aging, and to mark the transition of cognitively normal participants with preclinical AD to cognitive impairment. 2. Annually enroll and assess 35 new participants (CDR 0=23;CDR 0.5/AD =12) each year who are age e 65 to replenish the Core's cohort to maintain a sufficient sample size (n~250) to support the aims of the PPG and to supply study participants and their data (and DNA to Project 3) to individual Projects: 3. Follow all participants with annual assessments and provide diagnostic and clinical and cognitive data to all Cores and Projects, working closely with Core C: Biostatistics and Core A: Administration to coordinate data acquisition and management to integrate the Core's activities with the scientific goals of the Program Project. In addition to HASD's traditional diagnostic methods, in this application HASD participants will (in accordance with the criteria established by the Alzheimer Disease Neuroimaging Initiative-2) also be classified as significant memory concern, early and late mild cognitive impairment (MCI). 4. Support Core D: Neuropathology through our voluntary autopsy consent program. 5. Support Core E: Imaging and all Projects by referring: a. all HASD participants for MRI and PET amyloid imaging session at baseline and every 3 years thereafter;b. provide Project 1 (Indicators of transition to symptomatic AD) clinical characterizations and data from cognitive measures of all participants;c. refer to Project 2 (Sleep: potential prognostic and theranostic marker for preclinical AD) all participants for sleep and cerebrospinal fluid studies;d. Collect blood from all newly enrolled Core participants for Project 3 (Identification of genetic variants associated with the progression of AD) for their GWAS and variant characterization.
Core B: Clinical Project Narrative As instructed by the funding opportunity announcement for this application (PAR-13-329), only the Overall component contains a project narrative. Cores and projects were instructed not to include this section.
|Su, Yi; Blazey, Tyler M; Snyder, Abraham Z et al. (2015) Partial volume correction in quantitative amyloid imaging. Neuroimage 107:55-64|
|Shim, Yong Soo; Yang, Dong-Won; Roe, Catherine M et al. (2015) Pathological correlates of white matter hyperintensities on magnetic resonance imaging. Dement Geriatr Cogn Disord 39:92-104|
|Wang, Li-San; Naj, Adam C; Graham, Robert R et al. (2015) Rarity of the Alzheimer disease-protective APP A673T variant in the United States. JAMA Neurol 72:209-16|
|Ghoshal, Nupur; Perry, Arie; McKeel, Daniel et al. (2015) Variably Protease-sensitive Prionopathy in an Apparent Cognitively Normal 93-Year-Old. Alzheimer Dis Assoc Disord 29:173-6|
|Hurth, Kyle; Tarawneh, Rawan; Ghoshal, Nupur et al. (2015) Whipple's disease masquerades as dementia with Lewy bodies. Alzheimer Dis Assoc Disord 29:85-9|
|Aschenbrenner, Andrew J; Balota, David A; Tse, Chi-Shing et al. (2015) Alzheimer disease biomarkers, attentional control, and semantic memory retrieval: Synergistic and mediational effects of biomarkers on a sensitive cognitive measure in non-demented older adults. Neuropsychology 29:368-81|
|Lim, Miranda M; Gerstner, Jason R; Holtzman, David M (2014) The sleep-wake cycle and Alzheimer's disease: what do we know? Neurodegener Dis Manag 4:351-62|
|Pizzie, Rachel; Hindman, Halley; Roe, Catherine M et al. (2014) Physical activity and cognitive trajectories in cognitively normal adults: the adult children study. Alzheimer Dis Assoc Disord 28:50-7|
|Fagan, Anne M; Xiong, Chengjie; Jasielec, Mateusz S et al. (2014) Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. Sci Transl Med 6:226ra30|
|Harari, Oscar; Cruchaga, Carlos; Kauwe, John S K et al. (2014) Phosphorylated tau-A?42 ratio as a continuous trait for biomarker discovery for early-stage Alzheimer's disease in multiplex immunoassay panels of cerebrospinal fluid. Biol Psychiatry 75:723-31|
Showing the most recent 10 out of 529 publications